Abstract
Background Although sepsis is a life-threatening condition, its heterogeneous presentation likely explains the negative results of most trials on adjunctive therapy. This study in patients with sepsis aimed to identify subgroups with similar immune profiles and their clinical and outcome correlates.
Methods A secondary analysis used data of a prospective multicenter cohort that included patients with early assessment of sepsis. They were described using Predisposition, Insult, Response, Organ failure sepsis (PIRO) staging system. Thirty-eight circulating biomarkers (27 proteins, 11 mRNAs) were assessed at sepsis diagnosis, and their patterns were determined through principal component analysis (PCA). Hierarchical clustering was used to group the patients and k-means algorithm was applied to assess the internal validity of the clusters.
Results Two hundred and three patients were assessed, of median age 64.5 [52.0-77.0] years and SAPS2 score 55 [49-61] points. Five main patterns of biomarkers and six clusters of patients (including 42%, 21%, 17%, 9%, 5% and 5% of the patients) were evidenced. Clusters were distinguished according to the certainty of the causal infection, inflammation, use of organ support, pro- and anti-inflammatory activity, and adaptive profile markers.
Conclusions In this cohort of patients with suspected sepsis, we individualized clusters which may be described with criteria used to stage sepsis. As these clusters are based on the patterns of circulating biomarkers, whether they might help to predict treatment responsiveness should be addressed in further studies.
Trial registration The CAPTAIN study was registered on clinicaltrials.gov on June 22, 2011, # NCT01378169.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01378169
Clinical Protocols
NA
Funding Statement
Grant from the Programme Hospitalier de Recherche Clinique of the French Ministry of Health (PHRC AOM 09143) and from the Institut Mérieux-Institut Pasteur collaborative research partnership. The study was sponsored by the Département de la Recherche Clinique et du Développement de l’Assistance Publique-Hôpitaux de Paris. This project was part of Advanced Diagnostics for New Therapeutic Approaches, a program dedicated to personalized medicine, coordinated by Mérieux Alliance and supported by the French public agency, OSEO. These funding sources had no role in the design of this study, analyses, interpretation of the data, or decision to submit the results.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was approved by the "Comit” de Protection des Personnes Ile de France XI" (#2010-A00908-31-10056) on September 13, 2010 and registered on clinicaltrials.gov (NCT01378169) https://clinicaltrials.gov/ct2/show/NCT01378169. According to French national regulations, written consent of the patients was required but waived for the unarousable ones, and obtained if the study still required specific samples when the patient awoke.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
↵^ Members of the Combined Approach for The eArly diagnosis of INfection in sepsis (CAPTAIN) study group is provided in the Acknowledgments (collaborators section).
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
NA